Anixa Biosciences Inc 8-K

What Happened

• On February 9, 2026, Anixa Biosciences, Inc. announced via press release that its Phase 1 ovarian cancer CAR‑T therapy trial showed encouraging patient survival data and that regulatory approval was granted to allow dose escalation beyond the doses in the original protocol. The press release was furnished as Exhibit 99.1 to the Form 8‑K.
• The company noted that some statements are forward‑looking and subject to risks and uncertainties.

Key Details

• Date filed: February 9, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Trial stage: Phase 1 clinical trial for an ovarian cancer CAR‑T therapy.
• Regulatory action: Approval obtained to escalate dosing above the originally planned protocol levels.
• Supporting material: Press release provided as Exhibit 99.1 to the filing.

Why It Matters

• For investors, encouraging survival signals in a Phase 1 trial can be an early positive indicator of potential clinical benefit, while dose escalation approval allows the company to test higher doses that might improve efficacy or define optimal dosing.
• This is still an early (Phase 1) development focused primarily on safety and initial signals, and the company cautioned that forward‑looking statements involve risks and uncertainties that could affect outcomes.